siRNA delivery system based on magnetic nanovectors: Characterization and stability evaluation

Abdelrahman, Mohammed; Douziech-Eyrolles, Laurence; Alkarib, Suad Y; Hervé-Aubert, Katel; Djemaa, Sanaa Ben; Marchais, H.; Chourpa, Igor; David, Stéphanie

doi:10.1016/j.ejps.2017.05.062

Cited by 14 publications

(8 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The CS polymers with a positive charge were dissolved in a sodium acetate buffer (3%, HAC) to obtain a 1 mg/mL working solution. Tripolyphosphate (TPP) was selected as an ionic crosslinker to connect the CS polymers (Abdelrahman et al, 2017). Then, 0.25 mL of siRNA (siPAK1 or siNC) in diethyl pyrocarbonate water (30 nmol/mL) was added to 1.0 mL of a TPP aqueous solution (0.5 mg/mL) for the mixture solution while stirring for 1 h. As illustrated in Figure 2B, the GCGA-siPAK1 was fabricated by dropwise adding of the mixture solution of the siRNA and TPP to 1.75 mL of the GCGA, GACS, and CS solutions (1 mg/mL, at a CS-to-TPP weight ratio of 4.7:1) under constant magnetic stirring (1,300 rpm) for 30 min at 25 • C. The final NP concentration was ∼0.75 mg/mL.…”

Section: Synthesis and Characterization Of Gcgamentioning

confidence: 99%

Dual-Targeting Nanoparticle-Mediated Gene Therapy Strategy for Hepatocellular Carcinoma by Delivering Small Interfering RNA

Zheng

Jiang

et al. 2020

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

As a gene therapy strategy, RNA interference (RNAi) offers tremendous tumor therapy potential. However, its therapeutic efficacy is restricted by its inferior ability for targeted delivery and cellular uptake of small interfering RNA (siRNA). This study sought to develop a dual-ligand nanoparticle (NP) system loaded with siRNA to promote targeted delivery and therapeutic efficacy. We synthesized a dual receptor-targeted chitosan nanosystem (GCGA), whose target function was controlled by the ligands of galactose of lactobionic acid (LA) and glycyrrhetinic acid (GA). By loading siPAK1, an siRNA targeting P21-activated kinase 1 (PAK1), a molecular-targeted therapeutic dual-ligand NP (GCGA–siPAK1) was established. We investigated the synergistic effect of these two targeting units in hepatocellular carcinoma (HCC). In particular, GCGA–siPAK1 enhanced the NP targeting ability and promoted siPAK1 cell uptake. Subsequently, dramatic decreases in cell proliferation, invasion, and migration, with an apparent increase in cell apoptosis, were observed in treated cells. Furthermore, this dual-ligand NP gene delivery system demonstrated significant anti-tumor effects in tumor-bearing mice. Finally, we illuminated the molecular mechanism, whereby GCGA–siPAK1 promotes endogenous cell apoptosis through the PAK1/MEK/ERK pathway. Thus, the dual-target property effectively promotes the HCC therapeutic effect and provides a promising gene therapy strategy for clinical applications.

show abstract

Section: Synthesis and Characterization Of Gcgamentioning

confidence: 99%

Dual-Targeting Nanoparticle-Mediated Gene Therapy Strategy for Hepatocellular Carcinoma by Delivering Small Interfering RNA

Zheng

Jiang

et al. 2020

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

show abstract

“…These NPs are considered to be superior to the currently commonly used contrast agents such as gadolinium‐based compounds in part due to their lower toxicity and increase in the proton relaxation resulting in lower detection limit . Therefore, SPIONs can be used as theranostic agents, allowing for simultaneous diagnosis and therapy . Lee et al.…”

Section: Cs‐based Theranosticsmentioning

confidence: 99%

Chitosan‐based multifunctional nanomedicines and theranostics for targeted therapy of cancer

Fathi

Majidi

Zangabad

et al. 2018

Medicinal Research Reviews

View full text Add to dashboard Cite

Nanotechnology as an emerging field has established inevitable impacts on nano-biomedicine and treatment of formidable diseases, inflammations, and malignancies. In this regard, substantial advances in the design of systems for delivery of therapeutic agents have emerged magnificent and innovative pathways in biomedical applications. Chitosan (CS) is derived via deacetylation of chitin as the second most abundant polysaccharide. Owing to the unique properties of CS (e.g., biocompatibility, biodegradability, bioactivity, mucoadhesion, cationic nature and functional groups), it is an excellent candidate for diverse biomedical and pharmaceutical applications such as drug/gene delivery, transplantation of encapsulated cells, tissue engineering, wound healing, antimicrobial purposes, etc. In this review, we will document, discuss, and provide some key insights toward design and application of miscellaneous nanoplatforms based on CS. The CS-based nanosystems (NSs) can be employed as advanced drug delivery systems (DDSs) in large part due to their remarkable physicochemical and biological characteristics. The abundant functional groups of CS allow the facile functionalization in order to engineer multifunctional NSs, which can simultaneously incorporate therapeutic agents, molecular targeting, and diagnostic/imaging capabilities in particular against malignancies. These multimodal NSs can be literally translated into clinical applications such as targeted diagnosis and therapy of cancer because they offer minimal systemic toxicity and maximal cytotoxicity against cancer cells and tumors. The recent developments in the CS-based NSs functionalized with targeting and imaging agents prove CS as a versatile polymer in targeted imaging and therapy.

show abstract

“…In particular, metallic nanometer-sized materials, such as silver, gold, copper and titanium, all show favorable physical and chemical properties, and significant antibacterial activity [ 93 ]. Besides, the metallic oxide iron oxide has the property of magnetism forms magnetic nanoparticles as a magnetic material [ 94 ].…”

Section: Drug Delivery Systems For Onsmentioning

confidence: 99%

Enhancing the Therapeutic Delivery of Oligonucleotides by Chemical Modification and Nanoparticle Encapsulation

Sun

Zhao

et al. 2017

Molecules

View full text Add to dashboard Cite

Oligonucleotide (ON) drugs, including small interfering RNA (siRNA), microRNA (miRNA) and antisense oligonucleotides, are promising therapeutic agents. However, their low membrane permeability and sensitivity to nucleases present challenges to in vivo delivery. Chemical modifications of the ON offer a potential solution to improve the stability and efficacy of ON drugs. Combined with nanoparticle encapsulation, delivery at the site of action and gene silencing activity of chemically modified ON drugs can be further enhanced. In the present review, several types of ON drugs, selection of chemical modification, and nanoparticle-based delivery systems to deliver these ON drugs are discussed.

show abstract

siRNA delivery system based on magnetic nanovectors: Characterization and stability evaluation

Cited by 14 publications

References 29 publications

Dual-Targeting Nanoparticle-Mediated Gene Therapy Strategy for Hepatocellular Carcinoma by Delivering Small Interfering RNA

Dual-Targeting Nanoparticle-Mediated Gene Therapy Strategy for Hepatocellular Carcinoma by Delivering Small Interfering RNA

Chitosan‐based multifunctional nanomedicines and theranostics for targeted therapy of cancer

Enhancing the Therapeutic Delivery of Oligonucleotides by Chemical Modification and Nanoparticle Encapsulation

Contact Info

Product

Resources

About